Fig. 6: Higher GAD1 expression is associated with worse outcome in Ras mutant patients.

A GAD1 mRNA expression from TCGA in primary colon cancer tumors. N = 196 patients with KRAS, NRAS, or BRAF mutant tumors; N = 201 patients with KRAS, NRAS, or BRAF wildtype tumors. Individual data points are shown and the median with interquartile range is represented. Data was analyzed with an unpaired t-test; ****P < 0.0001. B GAD1 mRNA expression from the Gene Expression Omnibus (GEO), accession GSE39582, in primary colon cancer tumors. N = 220 patients with KRAS or BRAF mutant tumors; N = 276 patients with KRAS or BRAF wildtype tumors. Individual data points are shown and the median with interquartile range is represented. Data was analyzed with an unpaired t-test; ****P < 0.0001. C Kaplan-Meier curve with univariate analysis of the survival of patients with KRAS, NRAS, or BRAF mutated CRC tumors based on high versus low expression of GAD1 (defined as above or below the median GAD1 mRNA expression z-score of 0.3). Data was extracted from the TCGA. N = 254 patients. Data was analyzed using a log-rank (Mantel-Cox test) and a hazard ratio (HR) with 95% confidence interval (CI) is reported. D Kaplan-Meier curve with univariate analysis of the survival of patients with KRAS or BRAF mutated CRC tumors based on high versus low expression of GAD1 (defined as above or below the median GAD1 mRNA expression of 3.4). Data was extracted from the GEO, accession GSE39582. N = 217 patients. Data was analyzed using a log-rank (Mantel-Cox test) and a hazard ratio (HR) with 95% confidence interval (CI) is reported. All schematics were made in or are from BioRender.